The latest price target for MAIA Biotechnology (AMEX:MAIA) was reported by Noble Capital Markets on February 21, 2023. The analyst firm set a price target for $14.00 expecting MAIA to rise to within 12 months (a possible 305.28% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for MAIA Biotechnology (AMEX:MAIA) was provided by Noble Capital Markets, and MAIA Biotechnology initiated their outperform rating.

There is no last upgrade for MAIA Biotechnology

There is no last downgrade for MAIA Biotechnology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MAIA Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MAIA Biotechnology was filed on February 21, 2023 so you should expect the next rating to be made available sometime around February 21, 2024.

While ratings are subjective and will change, the latest MAIA Biotechnology (MAIA) rating was a initiated with a price target of $0.00 to $14.00. The current price MAIA Biotechnology (MAIA) is trading at is $3.45, which is within the analyst’s predicted range.